SEQ ID NO:3 aligned with Biogen's SEQ ID NO:3

```
<!--StartFragment-->RESULT 1
AAB60699
ID    AAB60699 standard; protein; 302 AA.
XX
AC    AAB60699;
XX
DT    11-SEP-2003  (revised)
DT    22-MAY-2001  (first entry)
XX
DE    Mouse IgG signal/human BAFF-R/human IgG Fc fusion protein, BAFF-R-Fc.
XX
KW    Human BAFF-R; BAFF receptor; TNF family; immunoregulatory agent;
KW    immune-related disorder; B-cell growth inhibitor;
KW    B-cell maturation inhibitor; immunoglobulin production inhibitor;
KW    autoimmune disorder; B-cell lymphoproliferative disorder; hypertension;
KW    renal disorder; immunosuppressive disorder; HIV infection;
KW    organ transplantation; antiinflammatory; systemic lupus erythematosus;
KW    autoimmune haemolytic anaemia; Grave's disease; multiple myeloma;
KW    B-cell carcinoma; leukaemia; rapidly progressive glomerulonephritis;
KW    lymphoma; gene therapy; cancer; tumour; IgG Fc; fusion construct.
XX
OS    Homo sapiens.
OS    Mus sp.
OS    Chimeric.
XX
PN    WO200112812-A2.
XX
PD    22-FEB-2001.
XX
PF    16-AUG-2000; 2000WO-US022507.
XX
PR    17-AUG-1999;   99US-0149378P.
PR    11-FEB-2000; 2000US-0181684P.
PR    18-FEB-2000; 2000US-0183536P.
XX
PA    (BIOJ ) BIOGEN INC.
PA    (APOT-) APOTECH R & D SA.
XX
PI    Mackay F,  Browning J,  Ambrose C,  Tschopp J,  Schneider P;
PI    Thompson J;
XX
DR    WPI; 2001-202866/20.
DR    N-PSDB; AAF59999.
XX
PT    Inhibiting dendritic cell-induced B-cell growth, maturation and B-cell
PT    lympho-proliferative disorder by administering BAFF-receptor polypeptide,
PT    chimeric molecule comprising receptor or anti-BAFF-R antibody homolog.
XX
PS    Example 4; Fig 2; 59pp; English.
XX
CC    The invention relates to the use of a BAFF receptor (BAFF-R, also known
CC    as BCMA) protein, or a BAFF-R fusion protein as an agent for the
CC    treatment of a variety of immune-related disorders. BAFF-R is a member of
CC    the TNF (tumour necrosis factor) family, acting as an immunoregulatory
CC    agent, and also plays a role in the development of hypertension and
CC    related disorders. BAFF-R, fusion proteins containing it, and BAFF-R-
CC    specific antibodies can be used for inhibiting B-cell growth, dendritic
CC    cell-induced B-cell growth and maturation, and immunoglobulin production,
CC    and in the treatment of autoimmune disorders, B-cell lymphoproliferative
CC    disorders, hypertension and renal disorders. The BAFF-R proteins may also
CC    be used in the treatment of immunosuppressive disorders and HIV
```

```
CC     infection, and in patients undergoing organ transplantation. The BAFF-R
CC     proteins or BAFF-R specific antibodies may be used for treating,
CC     suppressing or altering an immune response involving a signalling pathway
CC     between BAFF-R and BAFF, thereby inhibiting inflammation. Since BAFF-R
CC     inhibits B-cell growth and maturation it is useful for treating diseases
CC     such as systemic lupus erythematosus, autoimmune haemolytic anaemia,
CC     Grave's disease, multiple myeloma, B-cell carcinomas, leukaemia, rapidly
CC     progressive glomerulonephritis, and lymphomas. Nucleic acids encoding
CC     human BAFF-R may be used in gene therapy to treat tumours, lymphomas,
CC     autoimmune disorders and inherited B-cell-associated disorders. The
CC     present sequence represents the BAFF-R fusion protein BAFF-R-Fc,
CC     comprising a mouse IgG-kappa signal sequence, residues 1-153 of human
CC     BAFF-R and a human IgG Fc sequence. (Updated on 11-SEP-2003 to
CC     standardise OS field)
XX
SQ     Sequence 302 AA;

  Query Match             100.0%;  Score 1643;  DB 4;  Length 302;
  Best Local Similarity   100.0%;  Pred. No. 6.4e-112;
  Matches  302;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 METDTLLLWVLLLWVPGSTGDVTMLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTC 60
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 METDTLLLWVLLLWVPGSTGDVTMLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTC 60

Qy         61 QRYCNASVTNSVKGVDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 120
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 QRYCNASVTNSVKGVDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD 120

Qy        121 VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN 180
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN 180

Qy        181 KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG 240
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG 240

Qy        241 QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP 300
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP 300

Qy        301 GK 302
              ||
Db        301 GK 302
<!--EndFragment-->
```